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ABSTRACT
We investigated the mechanisms by which protein
kinase C (PKC) regulates the expression of the
a2(I) collagen gene in normal dermal fibroblasts.
Reduction of PKC-a activity by treatment with
Go ¨697-6orbyoverexpressionofadominantnegative
(DN) mutant form decreased a2(I) collagen gene
expression. This decrease required a sequence ele-
ment in the collagen promoter that contains Sp1/Sp3
binding sites. Reduction of PKC-d activity by rottlerin
or overexpression of DN PKC-d also decreased a2(I)
collagen gene expression. This effect required a sep-
arate sequence element containing Sp1/Sp3-binding
sites and an Ets-binding site. In both cases, point
mutations within the response elements abrogated
the response to PKC inhibition. Forced overexpres-
sion of Sp1 rescued the PKC inhibitor-mediated
reductionincollagenproteinexpression.ADNAaffin-
ity precipitation assay revealed that inhibition of
PKC-d by rottlerin increased the binding activity of
endogenous Fli1 and decreased that of Ets1. On the
other hand, TGF-b1, which increased the expression
ofPKC-d,hadtheoppositeeffect,increasingthebind-
ing activity of Ets1 and decreasing that of Fli1. Our
results suggest that PKC-d is involved in the regula-
tion of the a2(I) collagen gene in the presence or
absence of TGF-b. Alteration of the balance of Ets1
and Fli1 may be a novel mechanism regulating a2(I)
collagen expression.
INTRODUCTION
Systemic sclerosis or scleroderma is an acquired disorder
which typically results in ﬁbrosis of the skin and internal
organs. Although the pathogenesis of this disease is still
unclear, it includes inﬂammation, autoimmune attack and
vascular damage, leading to the activation of ﬁbroblasts and
disturbed interactions with different components of the extra-
cellular matrix (ECM) (1,2). Thus, abnormal scleroderma
ﬁbroblasts which are responsible for ﬁbrosis may develop
from a subset of cells that have escaped from normal control
mechanisms (3,4). However, despite recent advances in
understanding the regulation of collagen gene expression,
the mechanisms responsible for the pathologic increase in
the expression of collagen genes in scleroderma have not
been elucidated.
Fibroblasts from affected scleroderma skin cultured in vitro
produce excessive amounts of various collagens, mainly type I
and type III collagens (5,6), and display increased transcrip-
tion of the corresponding genes (7,8). Many of the character-
istics of scleroderma ﬁbroblasts resemble those of normal
ﬁbroblasts stimulated by transforming growth factor (TGF)-
b1 (9,10), suggesting that the activation of dermal ﬁbroblasts
in scleroderma may be a result of stimulation by TGF-b sig-
naling (11,12). Thus, the inhibition of TGF-b signaling is
thought to be one of the most reliable approaches to the treat-
ment of scleroderma, and there have been several reports that
such an inhibition can decrease collagen expression in vivo or
in vitro (13,14).
Jimenez et al. recently demonstrated that the inhibition of
protein kinase C (PKC)-d by a speciﬁc inhibitor of PKC-d_
rottlerin or by the overexpression of the dominant negative
mutant form (DN) of PKC-d suppressed the expression of the
aI(I) and aI(III) collagen genes in both normal and sclero-
derma dermal ﬁbroblasts in vitro, without affecting the expres-
sion of other genes examined (15). Furthermore, they showed
that scleroderma cells display higher levels of immunoreactive
PKC-d protein using immunoﬂuorescence microscopy and
immunoblotting. Their results indicate that PKC-d may be
involved in the regulation of collagen genes in normal and
scleroderma ﬁbroblasts, and suggest that the inhibition of this
signaling pathway may be another therapeutic approach for
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doi:10.1093/nar/gki275this disease. However, the mechanisms by which collagen
gene expression is regulated by PKCs in human dermal ﬁbro-
blasts remain unclear.
In this study, we investigated the molecular mechanisms
regulating the expression of the a2(I) collagen gene by PKCs
in normal dermal ﬁbroblasts in vitro, and analyzed the asso-
ciation between PKCs and stimulation with TGF-b.
MATERIALS AND METHODS
Reagents
Calphostin C, rottlerin and Go ¨6976 were purchased from
Calbiochem (La Jolla, CA). Anti-type I collagen-UNLB was
obtained from SouthernBiotech (Birmingham, AL) (16–18).
Actinomycin D and the antibody for b-actin or HA were from
Sigma (St Louis, MO). Anti-PKC-a, PKC-d, Sp1, Sp3, poly-
clonal Ets1 and polyclonal Fli1 antibodies were from Santa
Cruz Biotechnology (Santa Cruz, CA). Anti-PKC-d_antibody
was from Upstate Biotechnology (Lake Placid, NY). Rabbit
anti-phosphoserine speciﬁc antibody was from Zymed Labor-
atories (San Francisco, CA). Mouse anti-phosphothreonine
and anti-phosphoserine antibodies were from Biomedia
(Foster City, CA). Mouse monoclonal antibodies for Ets1
and Fli1 were from US Biological (Swampscott, MA) and
BD Pharmingen (San Diego, CA), respectively. Recombinant
human TGF-b1 was from R & D systems (Minneapolis,
MN). FuGENE 6 was obtained from Roche Diagnostics
(Indianapolis, IN).
Cell cultures
Fibroblasts were obtained by skin biopsy from healthy donors.
Institutional review board approval and written informed con-
sent were obtained according to the Declaration of Helsinki.
Primary explant cultures were established in 75 cm
2 culture
ﬂasks in modiﬁed Eagle’s medium (MEM) supplemented with
10% fetal calf serum (FCS), 2 mM glutamine and 50 mg/ml
gentamycin, as described previously (19,20). Monolayer cul-
tures were maintained at 37 Ci n5 %C O 2 in air. Fibroblasts
between the third and sixth subpassages were used for
experiments.
Cell lysis and immunoblotting
Human dermal ﬁbroblasts were cultured until they were con-
ﬂuent, then the medium was collected. Remaining cells were
washed with cold phosphate-buffered saline (PBS) twice and
lysed in lysis buffer [5 mM Tris–HCl, pH 8.0, 150 mM NaCl,
0.02% sodium azide (NaN3), 0.1% sodium dodecyl sulfate,
1 mg/ml aprotinin, 1% NP-40, 0.5% sodium deoxycholate,
1 mM sodium orthovanadate and 100 mg/ml phenylmethyl-
sulfonyl ﬂuoride (PMSF)]. Aliquots of the conditioned
medium (normalized for cell numbers) or cell lysate (normal-
ized for protein concentrations as measured by the Bio-Rad
reagent) were separated using SDS–polyacrylamide gels and
transferred to nitrocellulose membranes. The membranes were
blocked for 1 h and incubated overnight at 4 C with anti-
body for type I collagen, HA or b-actin. The membranes
were washed in Tris-buffered saline (TBS) and 0.1%
Tween-20, incubated with secondary antibody, and washed
again. The detection was performed using the Enhanced
Chemiluminescence Detection system (Amersham, Arlington
Heights, IL).
To examine the amounts of immunoreactive PKC isozyme
a and d in the cell lysates, conﬂuent cells were washed with
PBS and lysed using lysis buffer (15). The Triton X-100-
supernatants were obtained by centrifuge. Aliquots containing
20 mg of lysate were electrophoresed on polyacrylamide gels.
Anti-PKC-a or anti-PKC-d antibody (Upstate Biotechnology)
was used as the primary antibody.
To examine the amounts of immunoreactive Sp1, Ets1 or
Fli1 in the cell lysates, conﬂuent cells were washed with PBS
and lysed using lysis buffer containing 10 mM Tris–HCl, pH
7.4, 150 mM NaCl, 1 mM EDTA, 1% NP-40, 50 mM sodium
ﬂuoride, 1 mM PMSF, 1 mM sodium orthovanadate, 1 mg/ml
leupeptin, 1 mg/ml aprotinin and 1 mg/ml pepstatin. Polyclonal
IgG anti-Sp1, Ets1 or Fli1 antibody was used.
RNA preparation and northern blot analysis
Total RNA was extracted using an acid guanidinium
thiocyanate-phenol-chloroform method and analyzed by
northern blotting, as described previously (19,21). RNA
was subjected to electrophoresis on 1% agarose/formaldehyde
gels and blotted onto nylon ﬁlters (Roche Diagnostics, Indi-
anapolis, IN). The ﬁlters were UV cross-linked, prehybridized,
and sequentially hybridized with cDNA probes. The following
cDNA probes were used: human a2(I) collagen Pst I-Hind III
fragments and GAPDH Hind III-Not I fragments. The mem-
branes were then washed and exposed to X-ray ﬁlm.
Immunoprecipitation
Levels of Phosphorylated Sp1 were examined by immuno-
precipitation using anti-Sp1 or rabbit anti-phosphoserine
speciﬁc antibodies as described previously (22). The same
membrane was then stripped and reprobed with anti-Sp1 anti-
body to show the total amount of Sp1.
To examine the levels of phosphorylated Ets1 or Fli1,
anti-polyclonal Ets1 or Fli1 antibody was used as described
previously (23). The immunocomplexes were resolved by
PAGE, transferred onto a membrane, and incubated with
mouse anti-phosphothreonine or anti-phosphoserine antibody.
As a loading control, immunoblotting was also performed
using mouse anti-monoclonal Ets1 or Fli1, respectively.
Immunofluorescence
Fibroblasts were grown in 4-well LAK TEK chambers (Nunc,
Naperville, IL) to subconﬂuence as described above. After
24 h of serum starvation, the cells were ﬁxed with 3.7% for-
maldehyde, permeabilized with 0.5% Triton X-100 in PBS
(PBST), and blocked with 10% FCS in PBST (20,24). The
cells were stained with anti-PKC-a and -d antibodies (Santa
Cruz Biotechnology) as primary antibodies, washed, and
incubated with FITC-conjugated secondary antibodies. To
visualize the ﬂuorescence, a Zeiss microscope was used.
DNA affinity precipitation assay
Two oligonucleotides containing biotin on the 50 nucleotide
of the sense strand were used in the assays. The sequences
of these oligonucleotides are as follows: (i) COL-EBS oligo,
50-GAAAGGGCGGGGGAGGGCGGGAGGATGCGGAGG-
GCGGAG, which corresponds to base pair  307 to  269 of
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Ets-binding site (EBS) and GC-box, which can function as
Sp1/3-binding sites (SBS); (ii) COL-EBS-M oligo, 50-GAAA-
GGGCGGGGGAGGGCGGGAGTATGCGGAGGGCGGAG,
which has a mutated EBS of COL-EBS oligo. These oligonuc-
leotides were annealed to their respective complementary
oligonucleotides, and double-stranded oligonucleotides were
gel-puriﬁed and used. Cell lysates were obtained using lysis
buffer(25).Poly(dI–dC)competitorwasincubatedwiththecell
lysates, followed by incubation with each double-stranded
oligonucleotide. After the incubation, streptavidin-agarose
(Sigma) was added to the reaction and incubated. The
protein–DNA–streptavidin–agarose complex was washed and
loaded onto a SDS–PAGE gel. Detection of Sp1, Ets1 or Fli1
was performed with polyclonal IgG anti-Sp1, Ets1 or Fli1
antibody.
Plasmid construction
The generation of a  3500COL1A2/CAT construct consisting
of the full-length human a2(I) collagen gene fragment linked
to the chloramphenicol acetyltransferase (CAT) reporter gene
and a series of 50-deletions of the COL1A2/CAT construct
were described previously (19,21,26). The substitution mutant
plasmids in the CAGA motif which can function as a Smad-
binding element (SBE) (located between bp  263 and  258)
(SBE-mutated construct), the substitution mutants in the
TCCTCC motifs (located between bp  128 and  123, or
 164 and  159), and the substitution mutants in all three
GC-boxes (located between bp  303 and  271) (SBS-
mutated construct) of bp  353 +58 deletion constructs of
COL1A2/CAT were also described previously (19,26,27).
Furthermore, point mutations changing GGAT to GTAT
were introduced into the EBS (located between bp  285
and  282) of the bp  353 +58 deletion construct of
COL1A2/CAT (EBS-mutated construct) and the SBS-
mutated construct (EBS/SBS-mutated construct) using the
QuickChange site-directed mutagenesis kit (Stratagene)
according to the manufacturer’s instructions. Mutation and
deletion constructs were veriﬁed by sequencing.
Three copies of the 12 bp oligonucleotide [from bp  131
to  120 of the a2(I) collagen promoter] containing the
TCCTCC motif were cloned in both orientations into the
pBL-CAT5 vector carrying thymidine kinase gene promoter
elements (21).
HA-tagged DN PKC-a, PKC-d or PKC-e, and HA-tagged
wild-type (WT) PKC-a were kindly provided by Dr Jae-Won
Soh (28). WT and DN PKC-d were kindly provided by
Dr Weiqun Li (29). DN PKC-e was kindly provided by
Dr Alex Toker (Deaconess Medical Center, Boston, MA) (30).
The expression vectors for Sp1 and Sp3 were kindly pro-
vided by Dr Guntram Suske (31,32), and the expression
vectors for Ets1 and Fli1 were kindly provided by Dr Maria
Trojanowska (33). Plasmids used in the transient transfection
assays were puriﬁed twice on cesium chloride gradients as
described previously (21). At least two different plasmid
preparations were used for each experiment.
Transient transfection
Fibroblasts were grown to 50% conﬂuence in 100 mm dishes
in MEM with 10% FCS. The medium was replaced with
serum-free medium, and ﬁbroblasts were transfected with
the a2(I) collagen promoter constructs, expression vectors
or corresponding empty constructs, employing FuGENE6
as described previously (34). In order to correct minor vari-
ations in transfection efﬁciency, pSV-b-galactosidase vector
(Promega, Madison, WI) was included in all transfections.
After 48 h of incubation, cells were harvested in 0.25 M
Tris–HCl, pH 8 and fractured by freeze-thawing. Extracts,
normalized for protein content as measured with the Bio-
Rad reagent, were incubated with butyl-CoA and [
14C]-chlor-
amphenicol for 90 min at 37 C. Butylated chloramphenicol
was extracted using an organic solvent (2:1 mixture of tetra-
methylpentadecane and xylene) and quantitated by scintilla-
tion counting. Each experiment was performed in duplicate.
Statistical analysis
Statistical analysis was carried out with the Mann-Whitney
test for comparison of means. P values <0.05 were considered
signiﬁcant.
RESULTS
The effects of PKC inhibition on the expression of
type I procollagen protein or the a2(I) collagen gene
in normal dermal fibroblasts
First, we examined the effects of PKC inhibitors, calphostin C
(whole PKC inhibitor), rottlerin and Go ¨6976 (speciﬁc PKC-a
inhibitor), on the expression of type I procollagen in dermal
ﬁbroblasts by immunoblotting. As shown in Supplementary
Figure 1A and B, two polypeptides, corresponding to the two
chains of type I procollagen, were detected in the conditioned
medium and cell lysates. It has been already shown that the
altered ratio of the a1(I) to a2(I) chain is attributed to the
difference in the immunoreactivity of anti-type I collagen
antibody to the a1(I) and a2(I) chain (18). PKC inhibitors
both decreased the secretion of type I procollagen into con-
ditioned medium and reduced the deposition of type I procol-
lagen in the cell lysates. To note, rottlerin had the greatest
inhibitory effect (over 80% reduction), which was consistent
with previous reports (15), whereas Go ¨6976 decreased the
levels of type I procollagen modestly (almost 50% reduction).
These results suggest that PKCs are involved in the basal
expression of type I procollagen in dermal ﬁbroblasts.
To determine whether the reduction of type I procollagen
protein expression by these reagents was correlated with the
corresponding mRNA levels, human dermal ﬁbroblasts were
incubated in the presence or absence of these inhibitors under
the same conditions, and mRNA expression was analyzed
by northern blotting. The a2(I) collagen mRNA level was
signiﬁcantly reduced after the stimulation with these reagents
in comparison with the control level (Supplementary
Figure 1C). However, the expression of GAPDH mRNA
was not affected by these inhibitors, demonstrating that the
indicated concentration of these inhibitors did not have gen-
eralized toxic effects. Thus, the effect of these inhibitors on
the type I procollagen protein level paralleled that on the
mRNA level.
The steady-state level of mRNA can be affected by the
level of gene transcription and/or the stability of mRNA.
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levelsafter thetreatmentwith PKCinhibitorstakesplaceatthe
transcriptionallevel ortheposttranscriptionallevel, wewished
to determine whether these reagents decreased the stability of
the a2(I) collagen mRNA. Following the inhibition of tran-
scription by the addition of actinomycin D, the loss of a2(I)
collagen mRNA treated by the inhibitors was not signiﬁcantly
different from that observed in the untreated cells (Supple-
mentary Figure 1D). The failure of these inhibitors to decrease
the half-life of a2(I) collagen mRNA suggests that a2(I) col-
lagen gene expression is regulated at the level of transcription
by these inhibitors.
To conﬁrm this, we determined the effects of these reagents
on the a2(I) collagen promoter activity in dermal ﬁbroblasts
by conducting transient transfection assays using the full-
length COL1A2/CAT construct. a2(I) collagen promoter
activity was reduced by treatment with these inhibitors for
24 h to the same extent as the level of protein or mRNA
(Supplementary Figure 1E). These results suggest that the
basal activity of PKC is essential to maintain the basal tran-
scriptional activity of the a2(I) collagen gene.
Several investigators doubt the speciﬁcity of Go ¨6976 and
rottlerin toward PKC-a and -d, respectively (35,36). Thus, we
examined the effects of DN PKC-a or -d on the expression of
type I procollagen protein. The overexpression of these con-
structs also reduced the expression of type I procollagen pro-
tein in a dose-dependent manner (Supplementary Figure 1F),
whereas DN PKC-e had no effect, although HA-recombinant
proteins were expressed at similar levels. These results con-
ﬁrm that basal type I procollagen protein or a2(I) collagen
gene expression in normal ﬁbroblasts is regulated by at least
two signaling pathways, PKC-a and PKC-d.
Functional analysis of the a2(I) collagen promoter
by PKCs in normal fibroblasts
To identify potential regulatory elements of the human a2(I)
collagen gene by Go ¨6976 or DN PKC-a, we performed tran-
sient transfection assays using a series of 50-deletions of the
a2(I) collagen promoter linked to the CAT reporter gene.
Basal promoter activities of these constructs have been well
examined previously (21).
E
Figure 1. Identification of the a2(I) collagen promoter region mediating PKCs signaling in dermal fibroblasts. (A) The a2(I) collagen promoter deletion
constructs were treated with Go ¨6976, or co-transfected with WT or DN PKC-a. The open bar graph represents fold-increase in the promoter activity on treatment
with2mMofGo ¨6976for24hrelativetothepromoteractivitywithvehicle,whichwasarbitrarilysetat1.Thedottedorclosedbargraphsrepresentsfold-increasein
thepromoteractivityonco-transfectionwithDN(dottedbar)orWT(closedbar)PKC-arelativetothatwithemptyvector(0.5mg),whichwasarbitrarilysetat1.The
mean – SE from four independent experiments is presented. *P < 0.05 as compared with the value in cells treated with vehicle or cells co-transfected with empty
vector. (B) The diagram on the left indicates the mutant TCCTCC motif. Sequences with mutated nucleotides are indicated in boldface. Mutated plasmids were
transfectedinfibroblastsasdescribedin Figure1A.(C) Theindicatedplasmids(2mg)weretransfectedintofibroblastsasdescribedinFigure1A.(D)Theindicated
a2(I)collagenpromoterdeletionconstructsweretransfectedwith3mMofrottlerinand0.5mgofDNPKC-d orWTPKC-d asdescribedinFigure1A.Openbar,cells
treated with rottlerin; dotted bar, cells transfected with DN PKC-d; and closed bar, cells transfected with WT PKC-d.( E) Mutated plasmids were transfected with
rottlerin, DN PKC-d or WT PKC-d as described in Figure 1D. SBE, Smad-binding element; EBS, Ets-binding site; and SBS, Sp1/3-binding site.
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responded to Go ¨6976 or DN PKC-a, but the subsequent bp
 108 +58 construct showed little reactivity (Figure 1A). On
theotherhand,theoverexpressionofWTPKC-adidnotaffect
any of these deletion constructs. The results indicate that the
PKC-a inhibitor-response element is located between bp
 148 and  108 in the a2(I) collagen promoter, and that
the signaling activity of PKC-a is saturated in normal dermal
ﬁbroblasts.
This region contains the TCCTCC motif, which can func-
tion as SBS in the a2(I) collagen promoter (19) as well as
integrin av promoter (37). To determine whether this motif
contributed to the PKC-a-mediated promoter activity, the
effects of substitution mutations in the TCCTCC motif
were investigated (Figure 1B). The a2(I) collagen promoter
constructs carrying substitution mutations between bp  128
and  123 were unresponsive to Go ¨6976 treatment or co-
transfection with DN PKC-a. None of the other substitution
mutations in this promoter affected the effects of Go ¨6976
or DN PKC-a.
To further elucidate whether the TCCTCC sequence from
the a2(I) collagen promoter mediated the effects of Go ¨6976
or DN PKC-a using a heterologous promoter, three copies
of the 12 bp oligonucleotide (from bp 131 to 120) containing
the TCCTCC motif were cloned in both orientations into the
pBL-CAT5 vector carrying thymidine kinase gene promoter
elements. The vector construct pBL-CAT5 alone was not
affected by PKC-a inhibitors, whereas the insertion of
‘TCC’ oligonucleotides consistently resulted in a modest
reduction in promoter activity by the inhibitors, independent
of orientation (Figure 1C), which is similar to the previous
report (21). These results suggest that PKC-a mediates the
basal a2(I) collagen gene expression through the TCCTCC
motif speciﬁcally in dermal ﬁbroblasts.
Next, we examined the potential regulatory elements of the
human a2(I) collagen gene by rottlerin or DN PKC-d. Tran-
sient transfection assays using a series of 50-deletions of the
a2(I) collagen promoter revealed that the bp  353 +58
construct and the longer constructs responded to rottlerin or
DN PKC-d, but these inhibitors did not affect the promoter
activity of the subsequent bp  264 +58 construct, indicating
the PKC-d-inhibitor-response element is located between bp
 353 and  264 (Figure 1D). On the other hand, unlike WT
PKC-a, the overexpression of WT PKC-d-induced promoter
activity, and their response element was also located between
bp  353 and  264 in the a2(I) collagen promoter. This result
conﬁrms the PKC-d responsive element, and indicates that the
signaling activity of PKC-d is not saturated in normal dermal
ﬁbroblasts.
This PKC-d responsive element contains the EBS and
three GC-boxes, which can function as the SBS (23,26,
38). Thus, the effects of substitution mutations at these
binding sites were investigated (Figure 1E). Mutating all
three SBS resulted in a signiﬁcant reduction in reactivity
to rottlerin, DN or WT PKC-d, while mutating the EBS
had a signiﬁcant but weaker effect on the responsiveness.
Mutating both the EBS and the SBS resulted in a complete
abolishment of their effects. Mutating SBE did not affect the
reactivity. Thus, the integrity of both the SBS and the EBS
are thought to be critical for PKC-d-mediated basal a2(I)
collagen promoter activity.
Transcription factors involved in the a2(I) collagen
gene’s down-regulation by PKC inhibitors in
normal fibroblasts
Our results suggest that Go ¨6976 or DN PKC-a down-regulates
the a2(I) collagen gene expression via the SBS, whereas
rottlerin or DN PKC-d reduces it via the SBS and EBS. To
further investigate the involvement of Sp1/3 in the effects of
PKC inhibitors, we determined whether the amount of Sp1 or
Sp3 was affected by PKC inhibitors. Immunoblotting revealed
that the expression levels of these transcription factors in cell
lysates were not altered by the treatment with Go ¨6976 or
rottlerin (Figure 2A). Additionally, the phosphorylated levels
of Sp1 were also unchanged (Figure 2B).
On the other hand, we determined whether forced over-
expression of Sp1 or Sp3 could recover the PKC inhibitor-
mediated reduction in type I procollagen protein. Twenty-four
hours after transfection, the cells were treated with PKC
inhibitors, and 72 h later the medium was collected. Immun-
oblotting revealed that transient transfection of Sp1 itself did
not increase the expression of type I procollagen protein, but
recovered the reduction by Go ¨6976 or rottlerin in a dose-
dependent manner (Figure 2C). In particular, the effect of
Go ¨6976 was completely recovered by Sp1 overexpression.
The overexpression of Sp3 did not have such effects on
type I procollagen protein expression (Figure 2D). These res-
ults conﬁrm that Sp1 mediates the suppressive effects of PKC
inhibitors without altering the expression or phosphorylation,
and that PKC-a mediates basal collagen gene expression
mainly via Sp1.
Next, we examined how the Ets family was correlated with
the PKC-d-mediated basal a2(I) collagen gene expression. In
previous reports, both Ets1 and Fli1 were found to bind to the
EBS between bp  285 and  282 of the a2(I) collagen pro-
moter in a electrophoretic mobility shift assay using nuclear
extracts from normal dermal ﬁbroblasts. Furthermore, Ets1
and Fli1 had opposite effects on the a2(I) collagen gene
expression: Fli1 inhibited the a2(I) collagen promoter activity
by competing with Ets1 (23,38). Immunoblotting revealed that
the amount of Ets1 in cell lysates was reduced and that of Fli1
was increased after the stimulation with rottlerin compared
with the levels in control cells (Figure 2E). This indicated
that rottlerin reduces Ets1 expression which has a positive
effect on a2(I) collagenpromoter activity, and induces expres-
sion of Fli1 which has a suppressive effect.
Additionally, to determine the binding activities of Ets1 and
Fli1, we performed a DNA afﬁnity precipitation assay using
the COL-EBS oligo, containing the EBS and the SBS of the
a2(I) promoter. As a negative control, we used the COL-EBS-
M oligo, which has a mutated EBS of COL-EBS oligo. The
results showed that only the COL-EBS oligo bound endo-
genous Fli1 strongly after rottlerin treatment for 3 h, whereas
the binding of Ets1 to the EBS was decreased (Figure 2F).
EBS-M oligo did not bind Ets1 or Fli1 even after the treatment
with rottlerin. To note, the binding activity of Sp1 was
unchanged by rottlerin in both EBS oligo and EBS-M oligo,
however, it was decreased in EBS-M oligo. These results
suggest that Ets1 or Fli1 binds to this site in a speciﬁc manner,
and that the balance of Ets1 and Fli1 binding to the promoter
by rottlerin mediates the suppression of a2(I) collagen
promoter activity.
Nucleic Acids Research, 2005, Vol. 33, No. 4 1343On the other hand, levels of threonine- or serine-
phosphorylated Ets1 or Fli1 were unchanged by rottlerin
(Figure 2G).
The effect of exogenous TGF-b1 on PKC signaling in
normal fibroblasts
As shown above, the signaling activity of PKC-d is not sat-
urated in normal dermal ﬁbroblasts. The balance of Ets1 and
Fli1 mediated by the PKC-d signaling pathway may be a novel
mechanism regulating the basal a2(I) collagen expression.
Thus, we determined whether PKC-d or the balance of Ets1
and Fli1 is involved in the a2(I) collagen gene’s up-regulation
byexogenousstimuli, TGF-b1, as well as the basal expression.
First, to examine the expression levels of PKC-a and -d
protein in the presence or absence of TGF-b1, we performed
an immunoblot analysis using anti-PKC-a or -d antibodies.
Consistent with a previous report (39), TGF-b1 increased the
expression of PKC-d in dermal ﬁbroblasts (Figure 3A). In
contrast, PKC-a expression was not signiﬁcantly affected
by TGF-b1.
It is generally accepted that inactive PKC isoforms are
located in the nucleus or cytoplasm, and translocated to the
plasmamembraneand/orcytoskeletonafteractivation(40,41).
Immunoﬂuorescent labeling revealed that the stimulation of
dermal ﬁbroblasts with TGF-b increased the size of each cell.
Only PKC-d was translocated to the plasma membrane
and cytoskeleton in TGF-b1-treated dermal ﬁbroblasts
A
B
1344 Nucleic Acids Research, 2005, Vol. 33, No. 4(Figure 3B). These results indicate that PKC-d expression is
up-regulated and PKC-d is activated by the treatment with
TGF-b1.
As mentioned above, the overexpression of WT PKC-d
increased the promoter activity in dermal ﬁbroblasts, which
is abolished by mutating both EBS and SBS between bp  353
and  264 of the promoter. Thus, we speculated that TGF-b1
affects the SBS and EBS via the PKC-d signaling pathway.
Because the SBS, the so-called GC-box, has been reported to
be one of the TGF-b-response elements in the a2(I) collagen
promoter (42,43), we then wished to conﬁrm the involvement
of the balance of Ets1 and Fli1 on EBS in the TGF-b1 sig-
naling pathway. Thus, we determined the binding activities of
Ets1 and Fli1, by conducting DNA afﬁnity precipitation assays
using the COL-EBS oligo. In fact, the addition of TGF-b1
increased the binding of Ets1 to the EBS and decreased that of
Fli1 in normal ﬁbroblasts (Figure 3C), although TGF-b1 was
reported not to change Ets1 protein expression and to suppress
Fli1 protein expression (23,44). These results indicate that the
balance of Ets1 and Fli1 may also be involved in the TGF-b-
mediated up-regulation as well as rottlerin-mediated down-
regulation of the a2(I) collagen gene.
C
D
Nucleic Acids Research, 2005, Vol. 33, No. 4 1345DISCUSSION
The PKC family of proteins is composed of at least 10 iso-
zymes with diverse functions that are involved in numerous
important cellular processes, mediating the speciﬁc activation
of a variety of transcription factors, including AP-1 (45) and
NF-kB (46). However, no previous reports have discussed the
association between PKC and Sp1 or Ets family transcription
factors.
Previously, Go ¨6976 was shown to have little or no effect on
the a2(I) collagen mRNA expression or promoter activity in
renal mesangial cells (47). However, there was a large differ-
ence in the dose of this reagent between our study and theirs.
The expression of GAPDH mRNA was not affected in our
study, indicating that the inhibitory effect of Go ¨6976 was not
due to a generalized toxic effect. Furthermore, we conﬁrmed
the involvement of PKC-a in the regulation of a2(I) collagen
gene expression by the overexpression of DN PKC-a. Our
results suggest that Go ¨6976 as well as DN PKC-a down-
regulates a2(I) collagen gene expression via Sp1. However,
Go ¨6976 did not alter the total amount of Sp1 or the level of
phosphorylated Sp1. Although the mechanism by which Sp1
mediates the transcriptional regulation of the a2(I) collagen
gene by PKC signaling is presently unknown, it is possiblethat
PKCs affect the interaction of Sp1 with histones or other
E
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1346 Nucleic Acids Research, 2005, Vol. 33, No. 4chromatin components (20). Such a mechanism has recently
been described for the regulation of the mouse a2(I) collagen
promoter by TGF-b/TNF-a, where these cytokine treatments
affected the interaction of CTF/NF1 with histone H3 (48,49).
Our study indicated that PKC-d mediates a2(I) collagen
promoter activity via Sp1 and Ets1/Fli1 in normal ﬁbroblasts.
Synergism between Sp1 and Ets1 has been reported in para-
thyroid hormone-related protein promoters (50). Moreover,
Sp1 and Ets1/Fli1 cooperation is implicated in the regulation
of the a2(I) collagen promoter (23,38). Although rottlerin
altered the Ets1/Fli1 ratio in the EBS of the a2(I) collagen
promoter, this reagent did not change the levels of phos-
phorylated Ets1/Fli1 or binding activity of Sp1. Because
their nucleotide-recognition elements lie in relatively close
proximity, there may be synergism between Sp1 and Ets1/
Fli1 in the regulationofthis promoterthroughthe modiﬁcation
of chromatin structure. This speculation is supported by
the ﬁnding that the binding activity of Sp1 to GC-box is
decreased by the mutation in the EBS, as shown in
Figure 2F or Figure 3C.
G
Figure 2. Participation of transcription factors in the a2(I) collagen gene’s down-regulation by PKC inhibitors in normal fibroblasts. (A) To determine the
amountsofSp1orSp3incelllysates,fibroblastswereserum-starvedfor24handtreatedwithPKCinhibitorsfortheperiodindicated.Immunoblottingwasperformed
using anti-Sp1 or Sp3 antibody. The same membrane was then stripped and reprobed with anti-b-actin antibody as a loading control. (B) Dermal fibroblasts were
serum-starvedfor24handtreatedwithPKCinhibitorsfor24h.Celllysateswereimmunoprecipitatedwithanti-Sp1antibodytoexaminethephosphorylationlevels
ofSp1asdescribedin‘MaterialsandMethods’.Oneexperimentrepresentativeofthreeindependentexperimentsisshown.PhosphorylatedSp1levelsquantitatedby
scanningdensitometry andcorrectedforthetotal levelofSp1in thesame samplesareshownrelativeto thelevelin untreatedcells(1.0).(Cand D) Forimmunoblot
analysis,thetransienttransfectionoftheSp1orSp3expressionvectorinnormaldermalfibroblastswasperformedasdescribedin‘MaterialsandMethods’.Twenty-
four hours after the transfection, cells were treated with the indicated dose of PKC inhibitors for 72 h. Conditioned media and cell lysates (normalized for protein
concentrations as measured with the Bio-Rad reagent) were subjected to immunoblotting with anti-type I collagen antibody and antibody for HA or b-actin,
respectively.TypeIprocollagenproteinlevelsquantitatedbyscanningdensitometryandcorrectedforthelevelsofb-actininthesamesamplesareshownrelativeto
thelevelinuntreatedcells (1.0).(E)To determinetheamountsofEts1orFli1incell lysates,humandermalfibroblastswereserum-starved for24handtreatedwith
rottlerinfortheperiodindicated. Immunoblottingwasperformedusinganti-Ets1orFli1antibody.The samemembrane wasthenstrippedandreprobedwithanti-b-
actinantibodyasaloadingcontrol.(F)Celllysateswerepreparedfromnormalfibroblastsinthepresenceorabsenceofrottlerinfor12handincubatedwiththeCOL-
EBSoligoortheCOL-EBS-Moligoasdescribedunder‘MaterialsandMethods’.Proteinsboundtothesenucleotideswereisolatedwithstreptavidin-agarosebeads,
and Sp1, Ets1 or Fli1 was detected by immunoblotting. The levels of Ets1 (open bars) and Fli1 (closed bars) bound to COL-EBS oligo quantitated by scanning
densitometryareshownrelativetothelevelinuntreatedcells(1.0).Themean–SEfromfourindependentexperimentsispresented.*P<0.05ascomparedwiththe
valueinuntreatedcells.EBS,Ets-bindingsite.(G)Ets1orFli1phosphorylationonthreonine(toppanel)orserine(middlepanel)wasdeterminedinfibroblaststreated
with rottlerin for the indicated periods of time. Ets1 or Fli1 levels were determined using monoclonal anti-Ets1 or Fli1 antibody on the same filter (bottom panel).
Nucleic Acids Research, 2005, Vol. 33, No. 4 1347Deletion analysis of the human a2(I) promoter identiﬁed
active segments mediating basal promoter activity between bp
 376 and  108 (51). Although PKC-a- and PKC-d-response
elements shown by our results were included in this region,
these two signaling pathways acted on separate regions of the
promoter. It is known that each member of the PKC family can
have independent effects on a single gene regulation. Over-
expression of PKC-a or -d was reported to induce collagenase
promoter activity through a 12-O-tetradecanoylphorbol-13-
acetate-response element (52). On the other hand, PKC-a
and PKC-q are thought to have opposite effects on
calcineurin-regulated retinoid X receptor transcription during
T-cell activation (53). Furthermore, the response element of
PKC-a differs from that of PKC-q in the MDR1 promoter in
human breast carcinoma cells (54). A similar phenomenon
may occur in the regulation of a2(I) collagen gene expression.
We also conﬁrmed the association between PKC-d and
TGF-b1 stimulation. TGF-b-induced-PKC-d signaling affec-
ted the SBS and the Ets1/Fli1 ratio in the EBS leading to the
activation of the collagen promoter. The GC-boxes (42,43),
the AP-1 binding site (55) and the SBE (56) have been repor-
ted as TGF-b-response elements in the a2(I) collagen pro-
moter, and are located between bp  353 and  186 in the
promoter. Our results indicated that the EBS is also involved
in the TGF-b response, which is located in the same region.
We speculate that PKC-d translocated to the plasma mem-
brane and/or cytoskeleton that may regulate transcription of
the a2(I) collagen gene via downstream signaling cascades
A
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was recently reported that TGF-b activates ERK mitogen-
activated protein kinase, which is implicated in transcrip-
tional regulation by the Ets family, to enhance collagen
expression in which PKC-d may play some role (57,58).
The balance of Ets1 and Fli1 may be a novel mechanism
regulating a2(I) collagen expression. Taken together, our
results suggest that PKC-d is involved in the regulation
of the a2(I) collagen gene in the presence or absence of
TGF-b.
Kubo et al. reported that Fli1 protein expression is con-
sistently down-regulated in scleroderma dermal ﬁbroblasts
(44). The up-regulation of PKC-d and the down-regulation
of Fli1 in scleroderma may be caused by the stimulation of
TGF-b signaling. The inhibition of PKC-d may be effective
for the improvement of abnormal collagen overexpression.
Further clariﬁcation of the role of PKC-d in collagen
expression could provide a novel strategy for the treat-
ment of ﬁbrotic reactions, including those occurring in
scleroderma.
SUPPLEMENTARY MATERIAL
Supplementary Material is available at NAR Online.
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Figure 3. The effects of TGF-b1 on the expression of PKC-a and -d in normal fibroblasts. (A) To determine the amounts of PKC-a and -d in cell lysates,
fibroblastswereserum-starvedfor24handtreatedwithTGF-b1fortheperiodindicated.Immunoblottingwasperformedusinganti-PKC-aor-dantibody.Thesame
membrane was then stripped and reprobed with anti-b-actin antibody as a loading control. (B) The subcellular distribution of PKC-a and -d was visualized using
immunofluorescence.Fibroblastswereserum-starvedfor24handincubatedinthepresenceorabsenceofTGF-b1for1h.Magnification:·630.(C)Fibroblastswere
serum-starved for 24 h and treated with TGF-b1 (2 ng/ml) for 12 h. Cell lysates were incubated with the COL-EBS oligo or COL-EBS-M oligo as described under
‘Materials and Methods.’ Proteins bound to each nucleotide were isolated with streptavidin-agarose beads, and Sp1, Ets1 or Fli1 was detected by immunoblotting.
ThelevelsofEts1(openbars)andFli1(closedbars)boundtoCOL-EBSoligoquantitatedbyscanningdensitometryareshownrelativetothelevelinuntreatedcells
(1.0). EBS, Ets-binding site.
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